The Science Behind TIL and How Cells Fight Cancer

This episode takes a closer look at the biology behind TIL therapy. Medical oncologist James Smithy, MD, MHS, of Memorial Sloan Kettering Cancer Center breaks down tumor-infiltrating lymphocytes in plain language. He explains the 3 main types of T cells found within a melanoma tumor, including cells that target specific mutations like BRAF, cells that may also recognize normal pigment-producing cells (which can sometimes lead to patches of lighter skin or hair after treatment), and bystander cells. TIL therapy grows all of them together rather than picking one. Dr Smithy discusses why this is a fully personalized, not off-the-shelf treatment, using someone's own immune system as the foundation. He and acute care nurse practitioner Mary Montefusco, ACNP, walk through the tumor harvest process and how bridging therapy is tailored to each person during the 1- to 2-month wait for cells to be made.